Member Info for Matador78

Jesus Chills, is that it?

Chilston my old fruit.

Pose the question now.

Juvenescence

https://www.ft.com/content/ddec6a10-c046-11e9-b350-db00d509634e

https://appdevelopermagazine.com/developing-blockchain-dapps-with-factom-(fat-protocol)/

Pegnet launches in just over an hour

https://www.bbc.co.uk/news/world-africa-49377517

https://www.imgarena.com/about

This video's better

Because people are selling high risk to get into low risk cheap.

https://techcrunch.com/2019/08/15/launching-out-of-yc-blair-is-aiming-to-reshape-the-financing-of-college-tuition/?renderMode=ie11&guccounter=1&guce_referrer_us=aHR0cHM6Ly90ZWNoY3J1bmNoLmNvbS8yMDE5LzA4LzE1L2xhdW5jaGluZy1vdXQtb2YteWMtYmxhaXItaXMtYWltaW5nLXRvLXJlc2hhcGUtdGhlLWZpbmFuY2luZy1vZi1jb2xsZWdlLXR1aXRpb24v&guce_referrer_cs=IpZpWfbhYByvANkdW27dxQ

“In the second quarter we executed the complete relocation of our facilities including the construction of cGMP-capable therapeutics manufacturing space. We plan to utilize this new capability to produce clinical-grade master cell banks using our UniverCyte™ technology, as well as AGEX-BAT1 and AGEX-VASC1 that may be used in the future in clinical trials,” said Michael D. West, Ph.D., founder and Chief Executive Officer. “In addition, we have prioritized the advancement of our induced Tissue Regeneration (iTR) technology which is increasingly recognized by the industry as a potentially transformative platform technology for the treatment of human aging. Our appointment of Dr. Michael May to our Board of Directors will contribute to attaining our goal of leading the industry in the field of the biotechnology of aging. Lastly, we appreciate the support of our largest shareholder Juvenescence, Limited that provided a $2 million loan facility demonstrating their continued support of our product development. We are fortunate to have Juvenescence, which itself has raised over $110 million since 2017, as our key backer.”

“This is an exceptionally exciting time for us as we work toward our goal of becoming a leading biotechnology company in cellular therapies and human aging,” commented Greg Bailey, M.D., Chairperson of the Board of Directors. “Our commitment to this goal is demonstrated by us taking up residence in our new R&D facility as well as making progress in our work to engineer hypoimmunogenic cells and to move our other programs forward.”

Additional Recent Highlights

AgeX moved into a new San Francisco Bay Area R&D facility, comprising approximately 15,700-square-feet of office and lab space, located at 965 Atlantic Avenue Suite 101, Alameda, CA 94501. The new facility will house the company’s current staff and can accommodate for significant future growth. Good Manufacturing Practice (cGMP) production capability has been established at the new facility with two additional clean environmental space laboratories.
Dr. West and AgeX featured in a cover story in New Scientist magazine. The influential British science magazine’s Special Report, “A Cure for Aging?” ran in the April 27th issue.
The Company participated at three industry and investor conferences during the quarter. These included a presentation by Dr. West at Undoing Aging in Berlin, Germany, on AgeX’s regenerative medicine product development. At the conference, Dr. West also presented data relating to the central molecular clockwork mechanisms that AgeX is targeting with its induced iTR program. Additionally, during the quarter the company presented at Master Investor Show 2019 in London and Biotech Investing in Longevity in San Francisco.
AgeX entered into a Loan Facility Agreement with Juvenescence Limited, providing AgeX with a $2 million line of credit over the next 18 months to advance product development.

*Why: Current stablecoins (cryptocurrencies whose price are pegged to real-world assets) rely upon central parties and/or extremely complicated smart contracts. As a result, they're rarely improvements over legacy systems (trustworthy, transparent, auditable...).

*How: Miners validate trusted asset price data which allows for seamless conversion between assets with no central party. Once on exchanges, this will allow arbitrage traders to create liquidity and stability between the exchange price and PegNet published price.

*Benefit: No central party in charge of maintaining the stablecoins. No central party in charge of settling trades. No reliance on extremely complicated smart contracts. Just easy conversion between 32 assets while being highly #Transparent and auditable.

Without a doubt

Apologies, totally wrong board. I was at work at the time.

Hope everyone gets a good result whatevers going on here.

Tom Rooke (The BAT man) is now COO of EMMAC Life Sciences

The BAT man Tom Rooke is now Chief Operating Officer at Emmac Life Sciences

Have a look at what's happening in the world of Cannabis

https://www.businesswire.com/news/home/20190807005852/en/Silver-Spike-Acquisition-Corp.-Announces-Pricing-250

I imagine we'll be getting our debenture money back sooner rather than later judging by this.

"TORONTO, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Wayland Group (CSE:WAYL) (“Wayland”) and Cryptologic Corp. (CSE: CRY) (“Cryptologic”) are pleased to announce that Wayland has now received the previously announced $5 million bridge loan from Cryptologic, which has been advanced in connection with the proposed sale of Wayland’s Canadian business to Cryptologic.

“This bridge loan will allow Wayland to continue the build out of Wayland’s state-of-the-art EU-GMP certified facility in Langton, Ontario and to satisfy certain of the company’s existing liabilities. We intend to maintain a focus on financial and operational discipline in connection with our ongoing build-out of the Langton facility, and we thank our stakeholders for working with us through this phase in our development.”, said Paul Pathak, Chair of the Board.

The bridge loan is subordinate to Wayland’s existing secured convertible debentures, and Cryptologic will hold second-lien security over the assets to be purchased by Cryptologic in the proposed transaction.

Keep reading Chilpots You're in for a treat.

Better than a dog on both ears

I think Doggo just found something particularly significant.

BioTime’s promissory note due from Juvenescence Limited had an outstanding balance (principal plus accrued interest) of $22.9 million as of June 30, 2019. Unless earlier converted into Juvenescence ordinary shares, the promissory note is payable in cash, plus accrued interest at 7% per year, at maturity in August 2020. If Juvenescence completes an initial public offering (IPO) resulting in gross proceeds of not less than $50.0 million, the promissory note automatically converts into the Juvenescence securities issued in the IPO based on the per-share price to the public in the IPO, subject to an upward adjustment in the number of shares that would be issued to BioTime upon such conversion if the 20-day volume-weighted average trading price of one share of common stock of AgeX Therapeutics, Inc. (AgeX) before the IPO is priced above $3.00. If the promissory note is converted, the Juvenescence ordinary shares will be a marketable security that BioTime may use to supplement its liquidity, as needed and as market conditions allow.

http://www.iberianlawyer.com/news/news/9075-cannabis-company-terra-verde-advised-by-plmj-on-emmac-deal